Project to evaluate repurposing drugs to treat COVID-19
The Food and Drug Administration has partnered with the Critical Path Institute and National Center for Advancing Translational Sciences to launch the CURE Drug Repurposing Collaboratory, a forum for exchanging clinical practice data to inform potential new uses for existing drugs to treat unmet medical needs, beginning with COVID-19.
CDRC will use data collected via the CURE ID platform to aggregate global clinician treatment experiences and identify existing drugs that demonstrate possible treatment approaches warranting further study.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Flu cases are growing or likely growing in 39 states, according to the latest Centers for Disease Control and Prevention data from Nov. 11. COVID-19…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…